PeptideLabs Logo
PeptideLabs
All profiles

TB-500

Peptide · Tissue & repair

Is discussed experimentally for cell migration and wound repair; human efficacy is unproven.

Not FDA/EMA approvedWADA
LibraryNo account · this device only

Also known as: TB500 · Thymosin beta-4 fragment

Use at a glance

TB-500

Is discussed experimentally for cell migration and wound repair; human efficacy is unproven.

Which entry would you like to view?

Choose a source entry. Different products and study groups do not form one combined plan.

Online report · not medically verified

What amount?
2–2.5 mg
How often?
2 times per week
What time of day?
not reliably established
What period?
Week 1–6
How is it used?
Studies or online reports describe particular uses. They do not establish a general instruction for vendor products.
Does it need mixing?
No validated recipe is established for arbitrary research vials. The calculator shows concentration, not suitability or shelf life.
View preparationCheck sources
Overview of all entries

  • TB-500 · Week 1–6

    Online report · not medically verified

    2–2.5 mg · 2 times per week · not reliably established

  • TB-500 · Week 7–12

    Online report · not medically verified

    2–2.5 mg · once per week · not reliably established

  • TB-500 · pause

    Online report · not medically verified

    — · 4–8 weeks · not reliably established

More factsPeptide · Tissue & repair
Classification
Peptide · Tissue & repair
Research focus
Is discussed experimentally for cell migration and wound repair; human efficacy is unproven.
Evidence
Preclinical
Status
Not FDA/EMA approved

No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.

Schedule explained in detailCommunity/research information only

Amount status

Community source for the 7-amino-acid fragment: weeks 1–6, 2–2.5 mg twice weekly, then weeks 7–12, 2–2.5 mg once weekly. No validated human dose.

Profile evidence level: preclinical.

Timing

Two fixed weekdays online; full thymosin beta-4 is not interchangeable.

No individual recommendation.

Cycle/duration

After the described 12-week plan, usually a 4–8 week break; no confirmed safety limit.

No individual recommendation.

External community reference availableThe external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

External community reference available

The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

Open community source

Mixing & calculations

No validated recipe is established for arbitrary research vials. The calculator shows concentration, not suitability or shelf life.

Simple syringe and pen calculator

Choose your device and enter your known values. One result appears below.

You know the total solution volume. Calculate the scale mark for your entered amount.

Which syringe or pen?
More syringes
How much substance is in the vial?

Total amount on the label—not the container size in ml.

What is the total solution volume?

This is the total solution after dissolving, not automatically the water to add. Follow the specific product's instructions for preparation.

Which known amount do you want to convert?

Your known input. The calculator does not choose a suitable amount.

Complete the three number fields to see a result.

The calculator chooses neither a dose nor a mixing liquid. It does not check sterility, stability or suitability for use.

What the units mean
  • mg / µg = substance amount. 1 mg = 1,000 µg.
  • ml = liquid volume, not substance amount.
  • U / clicks = device markings. Their meaning depends on the device scale.
Calculation and extra figures

Complete the three number fields to see a result.

Scale and precision notes

Arithmetic does not establish measurement accuracy. Displayed numbers may be rounded; very small numbers use scientific notation. Intermediate values may not be readable on your device. Do not round fractional clicks up or down.

U-100 is used as a volume scale: 100 U = 1 ml. It is not the substance amount.

Copy this value from your pen's instructions. A 3 ml cartridge does not tell you the volume delivered at 60 clicks.

Source for the U-100 scale
Formulas and individual stepsOpen only if you want the deeper explanation.

Formulas used

  • Concentration (µg/ml) = vial mg × 1,000 ÷ fluid ml
  • Volume (ml) = target µg ÷ concentration
  • U-100 units = volume ml × 100

Mixing process described by the reference

01

Verify inputs

Independently check label, fluid, expiry information and planned volume. Do not use unclear or damaged products.

02

Disinfect stoppers

The reference calls for separate alcohol swabs and sterile single-use materials.

03

Add fluid slowly

The calculated fluid is described as running down the inside wall rather than being forced directly onto the powder.

04

Dissolve gently

The vial is rolled or swirled gently, not shaken, until no visible solids remain.

05

Inspect visually

Cloudy, discoloured or particle-containing solution is discarded. Clarity does not prove sterility or identity.

06

Label and store by product data

Record concentration and date. Reliable manufacturer or pharmacy information takes precedence.

An internet guide cannot ensure aseptic preparation. Bacteriostatic water, sterile water and approved product diluents are not interchangeable; benzyl alcohol may be unsuitable for some people.

See calculation examplesFollow sample figures to understand mg, ml and scale markings.

Documented vial and fluid examples

The table shows only the arithmetic for explicitly stated inputs. It confirms neither vial content nor stability, sterility or an appropriate target amount.

10 mg · assumed final volume: 2 ml

Community calculation example
Calculated amount2 mg
Concentration5,000 µg/ml
U-10040 U
Volume0.4 ml
Calculated amount2.5 mg
Concentration5,000 µg/ml
U-10050 U
Volume0.5 ml
All preparation informationProduct details and calculation examples from the available sources.

Community arithmetic: 10 mg +2 ml =5 mg/ml; 2 mg =40 U, 2.5 mg =50 U. Only for the exactly identified 7-AA TB-500 fragment; not for full thymosin beta-4.

Reconstitution & quantitiesOpen basics, units and sources
Explained in very simple termsBefore reading any number: this page reports what a product label, study or online community states. It does not say what any person should use.

Amount

mg or µg describe the mass of a substance. That is not the same as ml of fluid or U on a syringe. The number is only the amount stated by the identified source.

Interval

The interval only describes the time stated between two points. For example, once every 7 days does not mean daily and never justifies catching up or doubling.

Cycle

A cycle is a stated period that may include breaks. A community cycle proves neither effectiveness nor safety and does not prevent long-term risks.

Reconstitution

Reconstitution means mixing powder with a defined volume of fluid. This changes concentration, not the total amount in the vial. On U-100, 100 U equals exactly 1 ml of volume.

Not a guide to misuse

All community figures are shown only to place widely circulated online protocols in context. They are not instructions for self-use, injection, performance enhancement or any other misuse. Approved figures apply only to the exact named product, approved indication and medical supervision.

Research, risks & more detailsMechanism, adverse effects, storage, comparisons and common questions.

Mechanism: what is supported and what does not follow

Synthetic thymosin beta-4-related fragment

TB-500 is classified as “Synthetic thymosin beta-4-related fragment”. Is discussed experimentally for cell migration and wound repair; human efficacy is unproven. This describes the investigated pathway but does not validate a community use, amount, route or combination.

01

Cell migration peptide

This studies how a peptide influences the migration of cells toward an injury site, similar to workers rushing to a construction site. Speed and extent of cell migration are measured in lab models.

02

Actin-regulating peptide

This concerns effects on the cell-skeleton protein actin, which gives cells their shape and enables movement, like an internal scaffold. Researchers measure cell migration and wound closure in cell culture models.

03

Tissue repair models

Researchers use controlled wound or injury models in cells or animals to study how quickly and completely tissue heals after damage. Measures typically include wound size over time and markers of new tissue formation, similar to photographing a cut each day to see how fast it closes.

What communities discuss

These themes describe discussions and vendor claims. They do not prove benefit, safety, product identity or suitable use.

Wound healing anecdotes

People report perceived faster healing of injuries or tendon problems after using certain peptides, usually without a control group or objective measurement. Such individual reports do not establish actual efficacy or safety.

Recovery and injury forums

Personal recovery times after sports injuries while using different repair peptides are compared, often based on subjective pain scales. Such individual courses are influenced by many other factors and do not prove efficacy.

Bodybuilding forums

Here, muscle growth, strength gains, and recovery times are compared between different growth and repair peptides, often based on personal training logs. Vendor and user claims about muscle gains are anecdotal experience, not controlled study results.

Adverse effects and safety risks

  • Many so-called repair peptides lack controlled human studies. Unknown systemic effects, immune reactions, bleeding or vascular effects, and injection-related infection or contamination remain central risks.
  • Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
  • A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Do not self-use / obtain clinical review

  • Pregnancy, cancer, active infection, coagulation disorders, planned surgery and relevant immune disease call for especially strict professional assessment or avoidance.
  • Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
  • Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

  • There is no validated monitoring schedule for unapproved repair peptides. Clinical findings, signs of inflammation, blood count, liver/kidney function and coagulation may be relevant depending on the question.
  • Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

Preclinical

Confirmed human efficacy evidence is lacking.

Clinical evidence

Available data come mostly from animal or cell models; robust human efficacy and safety data are lacking.

TB-500 is a synthetic fragment related to thymosin beta-4, whereas BPC-157 derives from a different parent protein.

Storage and stability

  • The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
  • Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
  • Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.

Troubleshooting and common errors

  • U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
  • Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
  • Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
  • Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

Not FDA/EMA approved

No FDA- or EMA-approved medicinal product; efficacy and safety are not established.

Combinations / stacks

  • Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
  • Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
  • Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.

Back to all 64 profilesOpen scientific atlas profile